澤璟製藥(688266.SH):鹽酸吉卡昔替尼片治療重度斑禿的新藥上市申請獲得受理
格隆匯5月13日丨澤璟製藥(688266.SH)公佈,收到國家藥品監督管理局核准簽發的《受理通知書》,公司遞交的鹽酸吉卡昔替尼片治療重度斑禿的新藥上市申請(NDA)獲得受理,這是鹽酸吉卡昔替尼片第二個申請新藥上市的適應症。鹽酸吉卡昔替尼(曾用名:鹽酸傑克替尼)是一種新型的JAK抑制劑,對JAK激酶的四個亞型JAK1、JAK2、JAK3和TYK2都有顯著的抑制作用。吉卡昔替尼能夠有效抑制炎症和抑制T細胞過度激活,亦能顯著增加真皮層的厚度和促進毛囊再生,增加毛囊密度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.